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Abstract
Purpose The purpose of this study was to investigate the val-
ue of 18F-fluorodeoxyglucose positron emission tomography/
computed tomography (FDG PET/CT) parameters in the de-
tection of regional lymph node (LN) metastasis in patients
with cutaneous melanoma.
Methods We evaluated patients with cutaneous melanoma
who underwent FDG PET/CT for initial staging or recurrence
evaluation. A total of 103 patients were enrolled, and 165 LNs
were evaluated. LNs that were confirmed pathologically or by
follow-up imaging were included in this study. PET parame-
ters, including maximum standardized uptake value
(SUVmax), total lesion glycolysis and tumour-to-liver ratio,
were used to determine the presence of metastases, and the
results were compared with CT-determined LN metastasis.
Receiver operating characteristic (ROC) curve analysis was
used to determine the optimal cut-off values of the FDG
PET parameters.
Results A total of 93 LNs were malignant, and 84 LNs were
smaller than 10 mm. In all 165 LNs, an SUVmax of >2.51
showed a sensitivity of 73.1%, a specificity of 88.9%, and an
accuracy of 80.0% in detecting metastatic LNs. CT showed a
higher specificity (87.3%) and lower accuracy (65.5%). For
non-enlarged regional LNs (<10 mm), an SUVmax cut-off
value of 1.4 showed the highest negative predictive value
(81.3%). For enlarged LNs (≥10 mm), an SUVmax cut-off
value of 2.4 showed the highest sensitivity (90.7%) and accu-
racy (88.9%) in detecting metastatic LNs.
Conclusions In patients with cutaneous melanoma, an
SUVmax of >2.4 showed a high sensitivity (91%) and accu-
racy (89%) in detecting metastasis in LNs ≥1 cm, and LNs
<1 cm with an SUVmax <1.4 were likely to be benign.
Keywords Cutaneous melanoma . FDGPET/CT . Lymph
nodemetastasis . Sensitivity
Introduction
The incidence of cutaneous melanoma has shown a recent
increase in Western countries, and in low-incidence areas,
such as Asian countries. The World Health Organization
(WHO) classification of cutaneous melanoma categorizes
melanoma into four main subtypes, of which superficial
spreading melanoma is the most common in Caucasians. In
contrast, acral lentiginous melanoma [1] is the most common
in Asians and is generally detected during later stages com-
pared to other melanoma subtypes [2]. Also, due to the ag-
gressive nature of melanoma, prognosis is dependent on pre-
cise diagnosis and treatment. Patients with localized disease
have been reported to have a 5-year survival rate of 90%,
whereas if the disease has already spread at the time of diag-
nosis, the 5-year survival rate is 10%. As one of the most
common sites of metastasis has been reported to be the lymph
nodes (LN; 73.6% of cases) [3, 4], an evaluation of the imag-
ing modalities used for determining LN metastasis is needed.
Before surgical treatment and sentinel node biopsy, imag-
ing (ultrasonography for locoregional LN metastasis) is rec-
ommended for tumours of higher stages (pT1b–pT3a), and
computed tomography (CT) or 18F-fluorodeoxyglucose posi-
tron emission tomography/computed tomography (FDG PET/
CT) is recommended for tumours of stages >pT3a [5].
Although FDG PET has shown limited sensitivity for initial
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regional staging, especially in patients with American Joint
Committee on Cancer (AJCC) stage I and II disease [6],
FDG PET/CT is included in the imaging protocols of the
National Comprehensive Cancer Network guidelines for pa-
tients with stage III and IV disease and for patients with stage
IB or II disease with specific signs or symptoms [7]. Due to
the relatively high uptake of FDG in melanoma metastases,
combined with the often unpredictable metastatic pattern,
functional imaging with whole-body PET using FDG has
been shown to be useful for detecting metastasis [8, 9].
Studies evaluating clinically significant FDG uptake have
been performed for various malignancies, with one of the
most commonly evaluated malignancies being solid lung nod-
ules [10, 11] and mediastinal LNs in lung cancer patients [12].
In the evidence-based medicine era, criteria such as these are
helpful in guiding nuclear medicine specialists and clinicians
in determining malignancy. However, most studies evaluating
the clinical usefulness of FDG PET/CT for detecting metasta-
tic LNs in patients with melanoma have relied on visual
analysis.
The purpose of this study was to determine the value of
FDG PET/CT in detecting LN metastasis in patients with cu-
taneous melanoma.
Materials and Methods
Patient Selection and Clinical Characteristics
The medical records of patients with cutaneous melanoma
who underwent FDG PET/CT from January 2005 to
December 2015 for initial staging or recurrence evalua-
tion were reviewed. Contrast-enhanced CT (CE-CT) had
to have been performed within 2 weeks of FDG PET/CT
for the patient to be included in the study. A total of 103
patients were enrolled in the study. In patients who
underwent FDG PET/CT for melanoma staging, the nodal
stage was evaluated according to the seventh edition of
the AJCC staging manual, with LNs not detected on CE-
CT defined as Bclinically occult^ nodal metastases.
However, due to the low sensitivity of FDG PET/CT in
detecting microscopic LN metastases and the partial vol-
ume effect caused by very small LNs [9], LNs smaller
than 5 mm were excluded from the study. Also, only
LNs confirmed pathologically or on follow-up imaging
were included in the study. Positive findings on imaging
follow-up were defined as LNs that showed an increase in
size or newly developed necrotic components on follow
up CE-CT or ultrasonography. Finally, a total of 165 LNs
were evaluated. This study was approved by our institu-
tional review board, and informed consent was waived
due to the retrospective nature of the study.
PET/CT Imaging Protocol
PET/CT was performed on a Discovery STE scanner (GE
Healthcare, Milwaukee,WI) or a Biograph TruePoint 40 scan-
ner (SiemensMedical Systems, Knoxville, TN) equippedwith
16-slice or 40-slice CT, respectively. Patients fasted for at least
6 h before imaging, and the glucose level in the peripheral
blood was confirmed to be no more than 140 mg/dL prior to
injection of FDG. An FDG dose of approximately 5.5 MBq/
kg body weight was administered intravenously 1 h before
image acquisition. After the initial low-dose CT study
(Discovery STE 30 mA and 130 kVp; Biograph TruePoint
40 36 mA and 120 kVp), a standard PET protocol was used
to scan from the neck to the proximal thighs, with an acquisi-
tion time of 3min per bed position in three-dimensional mode.
Images were reconstructed using ordered subsets expectation
maximization (Discovery STE two iterations, 20 subsets;
Biograph TruePoint 40 three iterations, eight subsets).
FDG PET/CT and Contrast-Enhanced CTAnalysis
Two experienced nuclear medicine physicians reviewed all
PET/CT images. All images were evaluated on a lesion-by-
lesion basis. Metabolic parameters were measured usingMIM
software. A volume of interest was drawn on each LN based
on the contour seen on CT, and the maximum standardized
uptake value (SUVmax) was recorded. In cases where there
was a clear misregistration between the CT and PET images,
the centre of the volume of interest was moved to the centre of
the SUV. The relative SUVmax threshold (40%) was used to
define metabolic tumour volume (MTV). Total lesion glycol-
ysis (TLG) was calculated asMTV ×mean SUV (SUVmean).
Also, the SUVmean of the liver was determined by drawing
three regions of interest on the normal liver parenchyma and
obtaining the average SUV of these regions. The tumour-to-
liver ratio (TLR) was also calculated by dividing the SUVmax
of the LN by the SUVmean of the liver. CE-CT images were
reviewed, and standard criteria for LNmetastasis were used to
identify metastatic LNs (short-axis diameter ≥15 mm for neck
LNs, short-axis diameter ≥10 mm for non-neck LNs, or LNs
with necrotic components or perilesional infiltration regard-
less of size).
Statistical Analysis
Patient data were collected, and PETand CT data were record-
ed. The gold standard was LN metastasis determined either
pathologically or on follow-up imaging. SUVmax, TLG, and
TLR were evaluated as continuous variables, and Student’s t
test was performed for categorical variables. CT-determined
LNs were categorized as positive or negative, and chi-squared
analysis was performed. The Pearson correlation coefficient
was used to compare LN size with FDG uptake parameters.
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Receiver operating characteristic (ROC) curve analysis was
used to determine the optimal cut-off value of the FDG PET
parameters to determine the highest sensitivity for the detec-
tion of LN metastasis. This cut-off value was used to deter-
mine the sensitivity, specificity, and accuracy of PET/CT in
detecting LN metastasis. Differences between AUC values
from the ROC analysis were analysed using a Z test according
to the method of Hanley and McNeil. McNemar’s test was
used to compare FDG PET/CT and CE-CT for evaluating
LN metastasis. Finally, LNs were categorized as larger or
smaller than 10 mm, and McNemar’s test was used to com-
pare the sensitivity, specificity, and accuracy of CE-CT and
PET/CT in detecting metastatic LNs.
Results
Patient Characteristics
Of the 103 patients (57 men; mean age 59.3 ± 11.9 years) who
underwent FDG PET/CT, 67 (65%) underwent FDG PET/CT
for melanoma staging, and 36 (35%) underwent FDGPET/CT
for recurrence evaluation. A total of 165 LNs were assessed
either pathologically (139 LNs, 84.2%) or on imaging follow-
up (26 LNs, 15.8%). Of these 165 LNs, 93 (56.4%) were
determined to be metastatic, and 72 (43.6%) were determined
to be benign. Regarding size, 84 LNs (50.9%) were 5–10 mm
in diameter, and 81 LNs (49.1%) were larger than 10mm. The
average SUVmax of the LNs was 4.85 ± 6.43. The character-
istics of the 103 enrolled patients are summarized in Table 1
and of the 165 LNs evaluated are summarized in Table 2.
Analysis of Lymph Node Images
All FDG uptake parameters were significantly higher in met-
astatic LNs than in benign LNs (SUVmax 7.3 ± 7.6 vs.
1.6 ± 1.8, p < 0.001; TLG 43.2 ± 169.7 vs. 2.0 ± 9.3,
p = 0.022; TLR 3.0 ± 3.1 vs. 0.7 ± 0.8, p < 0.001, respective-
ly). Pathological LNs were significantly larger than benign
LNs (14.9 ± 8.5 mm vs. 8.8 ± 3.0 mm, respectively;
p < 0.001). FDG uptake was also significantly higher in met-
astatic LNs smaller than 10 mm than in benign LNs of the
same size (SUVmax 2.6 ± 2.1 vs. 1.4 ± 1.0, respectively;
p < 0.004; Table 3). SUVmax was significantly higher in
larger metastatic LNs (≥10 mm) than in smaller metastatic
LNs (<10 mm; p < 0.001), but there was no significant differ-
ence in SUVmax between larger and smaller benign LNs
(p = 0.190). TLG and TLR also showed similar trends
(Table 3).
The correlation between LN size and FDG uptake was
analysed using the Pearson correlation coefficient. There
was a significant but weak correlation between LN size and
FDG uptake (r = 0.517 for SUVmax, r = 0.576 for TLG,
r = 0.516 for TLR; p < 0.001 for all comparisons). When
LNs were categorizing as benign or malignant, there was still
Table 1 Clinicopathological characteristics of the 103 patients enrolled
Variable Value
PET/CT indication, n (%)
Staging 67 (65.0)




Age (years), mean ± SD 59.29 ± 11.89
Primary site, n (%)
Head and neck 12 (11.7)
Trunk 10 (9.7)
Upper extremity 12 (11.7)
Lower extremity 69 (67.0)







a Of the 67 patients who underwent PET/CT for staging
Table 2 Characteristics of the 165 LNs evaluated
Variable Value
Location of LNs, n (%)
Popliteal, inguinal, iliac 110 (66.7)
Axillary, supraclavicular, elbow 32 (19.4)
Mediastinal, neck 23 (13.9)
LN metastasis, n (%)
Positive 93 (56.4)
Negative 72 (43.6)
Metastasis confirmation method, n (%)
Pathological 139 (84.2)
Imaging follow-up 26 (15.8)
LN size (mm), mean ± SD 12.2 ± 7.3
LN size category, n (%)
5–10 mm 84 (50.9)
≥10 mm 81 (49.1)
CE-CT findings, n (%)
Positive LN 95 (57.6)
Negative LN 70 (42.4)
SUVmax, mean ± SD 4.85 ± 6.43
Tumour-to-liver ratio, mean ± SD 1.99 ± 2.63
Total lesion glycolysis, mean ± SD 32.71 ± 140.75
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a significant but weak correlation between LN size and FDG
uptake inmalignant LNs (r = 0.416 for SUVmax, r = 0.587 for
TLG, r = 0.414 for TLR; p < 0.001 for all comparisons), but
there was a minimal correlation in benign LNs (r = 0.372 for
SUVmax, r = 0.443 for TLG, r = 0.372 for TLR; p < 0.001 for
all comparisons).
Detection of LN Metastasis
The accuracy of FDG PET/CT and CE-CT in detecting me-
tastasis was evaluated for all LNs. First, ROC analysis was
performed to determine the cut-off values with the highest
sensitivity (Fig. 1). The cut-off values with the highest sensi-
tivities were 2.51 for SUVmax (area under curve, AUC,
0.864, p < 0.0001), 0.91 for TLR (AUC 0.858, p < 0.0001)
and 3.5 for TLG (AUC 0.831; p < 0.0001). Applying these
cut-off values, SUVmax showed high sensitivity (73.1%),
high specificity (88.9%), and high accuracy (80%) in detect-
ing metastasis in all LNs. In contrast, CE-CTshowed a similar
sensitivity (76.3%), but lower specificity (66.7%) and lower
accuracy (72.1%). The values for the other FDG parameters
are shown in Table 4. The AUC values of PET parameters
provided significantly better detection of metastatic LNs than
CE-CT (SUVmax vs. CE-CT Z = 3.745, p < 0.001; TLR vs.
CE-CT Z = 3.571, p < 0.001; TLG vs. CE-CT Z = 3.112,
p = 0.002). All other AUC comparison values were not sig-
nificant (p > 0.05). Finally, McNemar’s test revealed that there
was a significant difference in the detection of metastatic LNs
between SUVmax and CE-CT (p = 0.003) and between TLG
and CE-CT (p < 0.001).
For the 81 LNs ≥10 mm, the optimal cut-off values from
the ROC analysis were 2.4 for SUVmax (AUC 0.881,
p < 0.0001), 1.05 for TLR (AUC 0.892, p < 0.0001), and
3.46 for TLG (AUC 0.834, p < 0.0001). In this group of
LNs, SUVmax showed high sensitivity (90.7%), high speci-
ficity (82.4%), and high accuracy (88.9%) in detecting LN
metastasis. On CE-CT, all lesions were considered to be pos-
itive, resulting in 100% sensitivity and 0% specificity.
Finally, for the 84 LNs <10 mm, the optimal cut-off values
were 1.4 for SUVmax (AUC 0.723, p = 0.0002), 0.68 for TLR
(AUC 0.691, p = 0.004), and 1.55 for TLG (AUC 0.637,
p = 0.049; Fig. 2). In this group of LNs, SUVmax showed a
sensitivity of 69.0%, a specificity of 71.0%, and an accuracy
of 70.3%. Although the SUVmax cut-off value of 1.4 had a
very low positive predictive value (PPV) for detecting metas-
tases (55.6%), its negative predictive value (NPV) was rela-
tively high (81.3%), which suggests that minimal FDG uptake
in non-enlarged regional LNs most likely signifies that the
LNs are benign (Fig. 3). In contrast, CE-CT showed very
low sensitivity (24.1%), slightly higher specificity (87.3%),
and lower accuracy (65.5%) than the PET parameters. Other
PET parameters are shown in Table 4. The SUVmax AUC
was significantly higher than the CE-CT AUC (Z = 2.089,
p = 0.036) and higher than the TLG AUC (Z = 2.142,
p = 0.032). McNemar’s test showed that the rate of detection
ofmetastatic LNswith CE-CTwas significantly different from
Fig. 1 Receiver operating characteristic curve analysis of FDG PET/CT
parameters for all LNs. The optimal cut-off values are 2.51 for SUVmax
(AUC 0.864, p < 0.0001), 0.91 for TLR (AUC 0.858, p < 0.0001), and 3.5
for TLG (AUC 0.831, p < 0.0001). The CE-CT AUC is 0.715
(p < 0.0001). The AUCs for all PET parameters were significantly higher
than the CE-CT AUC (p < 0.05; individual p values are provided in the
main text)
Table 3 Imaging correlations for lymph node metastases according to
lymph node size
Variable Metastatic Benign p value
All LNs (n = 165)
Number of LNs 93 72 –
SUVmax 7.3 ± 7.6 1.6 ± 1.8 <0.001
Total lesion glycolysis 43.2 ± 169.7 2.0 ± 9.3 0.022
CE-CT size (mm) 14.9 ± 8.5 8.8 ± 3.0 <0.001
Tumour-to-liver ratio 3.0 ± 3.1 0.7 ± 0.8 <0.001
CT short axis <10 mm
(n = 84)
Number of LNs 29 55 –
SUVmax 2.6 ± 2.1 1.4 ± 1.0 0.004
Total lesion glycolysis 2.03 ± 3.1 0.8 ± 1.5 0.043
Tumour-to-liver ratio 1.1 ± 0.8 0.6 ± 0.4 0.005
CT short axis ≥10 mm
(n = 81)
Number of LNs 64 17 –
SUVmax 9.5 ± 8.2 2.5 ± 3.2 <0.001
Total lesion glycolysis 61.9 ± 202.2 6.1 ± 18.8 0.262
Tumour-to-liver ratio 3.9 ± 3.3 1.0 ± 1.4 <0.001
The data presented are means ± SD
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the rates of detection with SUVmax (p < 0.001) and TLR
(p = 0.003), but not different from the rate with TLG
(p = 0.263).
Discussion
The present study evaluated various FDG parameters and
CE-CT for detecting LN metastasis in patients with cuta-
neous melanoma. We showed that, the use of an SUVmax
cut-off value of 2.5 was associated with an accuracy of
80.0%, which was superior to that of CE-CT (72.1%). For
LNs smaller than 10 mm, SUVmax showed a much
higher sensitivity than CE-CT in detecting LN metastasis.
TLR showed similar results to those with SUVmax, but
TLG showed lower sensitivity than the other PET param-
eters. Overall, FDG PET/CT showed a higher diagnostic
value than conventional anatomical images in this cohort
of patients with cutaneous melanoma. In a recent study, N
and M stages were correctly determined by PET/CT in
243 of 250 patients (97.2%; 95% CI 95.2–99.4%) com-
pared with 197 patients (78.8%; 95% CI 73.7–83.9%) by
CT [13]. In this study, FDG PET/CT showed a higher
value than CE-CT in detecting LN metastasis.
The clinical significance of this study is that it is one of
the largest studies to use semiquantitative analysis to eval-
uate the ability of FDG PET/CT to detect LN metastasis.
There have been many studies over the past decade that
have evaluated the ability of FDG PET/CT to detect LN
metastasis, although all but two studies used visual anal-
ysis to determine metastasis [1, 13–19]. Although visual
analysis is generally used in the clinical setting, a more
objective method may be more helpful when comparing
the results of different studies. In one of the two studies
that used SUVmax, a cut-off value of 2.5 was chosen, but
Table 4 Accuracy of PET/CT parameters for the detection of lymph node metastasis





ALL LNs (n = 165)
SUVmax >2.51 68/93 (73.1%) 64/72 (88.9%) 68/76 (89.5%) 64/89 (71.9%) 132/165 (80.0%)
Tumour-to-liver ratio >0.91 72/93 (77.4%) 60/72 (83.3%) 72/84 (85.7%) 60/81 (74.07%) 132/165 (80.0%)
Total lesion glycolysis >3.5 61/93 (65.6%) 66/72 (91.7%) 61/67 (91.0%) 66/98 (67.4%) 127/165 (77.0%)
CE-CT 71/93 (76.3%) 48/72 (66.7%) 71/95 (74.7%) 48/70 (68.6%) 119/165 (72.1%)
CT short axis <10 mm
(n = 84)
SUVmax >1.4 20/29 (69%) 39/55 (71%) 20/36 (55.6%) 39/48 (81.3%) 59/84 (70.3%)
Tumour-to-liver ratio >0.68 17/29 (58.6%) 42/55 (76.4%) 17/30 (56.7%) 42/54 (77.8%) 59/84 (70.3%)
Total lesion glycolysis >1.55 15/29 (51.7%) 46/55 (83.6%) 15/24 (62.5%) 46/60 (76.7%) 61/84 (72.6%)
CE-CT 7/29 (24.1%) 48/55 (87.3%) 7/14 (50%) 48/70 (68.6%) 55/84 (65.5%)
CT short axis ≥10 mm (n = 81)
SUVmax >2.4 58/64 (90.7%) 14/17 (82.4%) 58/61 (95.1%) 14/20 (70%) 72/81 (88.9%)
Tumour-to-liver ratio >1.05 57/64 (89.1%) 13/17 (76.5%) 57/61 (93.5%) 13/20 (65%) 70/81 (86.5%)
Total lesion glycolysis >3.46 56/64 (87.5%) 14/17 (82.4%) 56/59 (94.9%) 14/22 (63.6%) 70/81 (86.5%)
CE-CT 64/64 0/17 64/81 (79.1%)
Fig. 2 Receiver operating characteristic curve analysis of FDG PET/CT
parameters for LNs <10 mm. The optimal cut-off values are 1.4 for
SUVmax (AUC 0.723, p = 0.0002), 0.68 for TLR (AUC 0.691,
p = 0.004), and 1.55 for TLG (AUC 0.637, p = 0.049). The CE-CT
AUC is 0.557 (p = 0.3936). The SUVmax AUC is significantly higher
than the CE-CT AUC (p = 0.036) and higher than the TLG AUC
(p = 0.032)
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this was arbitrarily determined [19]. More recently, Giesel
et al. used SUVmax to detect LN metastasis in patients
with cutaneous melanoma, as well as in patients with oth-
er malignancies, but they defined positive LNs as those
with an SUVmax three times greater than the blood pool
[15]. Similarly, we found that SUVmax adjusted to liver
activity (TLR) showed similar diagnostic accuracy to
SUVmax. In contrast, TLG showed significantly worse
diagnostic accuracy than SUVmax, which is probably
due to the contribution of the size component to the cal-
culation of TLG. Overall, we showed that a few cut-off
values could serve as guidelines in the detection of LN
metastasis in patients with cutaneous melanoma, although
further studies are needed to confirm our results.
We evaluated the sensitivity and specificity of FDG PET/
CT in detecting metastatic LNs smaller than 10 mm. It is well-
established that FDG PET/CT shows low sensitivity in detect-
ing clinically occult (nonpalpable) LN metastasis [9, 14], and
studies have suggested that FDG PET/CT is not suitable for
determining the presence of LN micrometastasis [19].
However, PET/CT is often acquired to evaluate recurrence
or for staging of melanoma in patients who might have in-
transit metastasis without palpable LNs (N2c) or clinically
occult regional metastatic LNs (N2a). Therefore, we included
these smaller LNs (5–10 mm) to evaluate FDG PET/CT for
assessing regional LNs with a high rate of metastasis. In re-
gional or in-transit clinically occult LN, an SUVmax higher
than 1.4 had a PPV of only 56% in detecting metastasis, but
had a high NPV (81%) in detecting nonmalignant LNs. CE-
CT showed a much lower PPV and NPV in detecting LN
metastasis than both SUVmax and TLR.
The limitations of this study are that, due its retrospective
nature, there was an inherent selection bias, which suggests
the need for more studies using semiquantitative analysis to
determine clinically significant cut-off values. Although we
evaluated many regional LNs, a larger study is needed to
confirm these results, as the relative number of metastatic
LNs confirmed pathologically or on follow-up imaging is
smaller for non-enlarged LNs.
Conclusions
In patients with cutaneous melanoma, an SUVmax higher
than 2.4 showed high sensitivity (91%) and accuracy (89%)
in detecting metastatic LNs ≥1 cm. LNs <1 cm with an
SUVmax lower than 1.4 were likely to be benign.
Fig. 3 Representative images of benign and malignant LNs in patients
with malignant melanoma. a–d A 57-year-old man who had cutaneous
melanoma on the sole of the right foot: the coronal (a) and transaxial (b)
PET images, and the PET/CT fusion image (c) show mild FDG uptake in
the right inguinal area (SUVmax 2.04, TLR 0.76, TLG 2.04), which
corresponds to a 9.7-mmLN seen on the CE-CT image (d). LNmetastasis
was confirmed by surgical excision. e–h A 62-year-old woman with
cutaneous melanoma on the sole of the left foot: the coronal (e) and
transaxial (f) PET images, and the PET/CT fusion image (g) show min-
imal FDG uptake in the left inguinal LN preoperatively (SUVmax 1.29,
TLR 0.62, TLG 1.18, size 8.7 mm), which corresponds to the lesion seen
on the CT image (h). Sentinel node biopsy showed no evidence of
metastasis
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